AG¡¤×ðÁú¿­Ê± - ÈËÉú¾ÍÊDz«!

ÈÕ±¾ÕZ
ÐÂÎÅÖÐÐÄ

9/25

2024

ϲѶ£¡º£ºÍÒ©Îï×Ïɼ´¼¿Ú·þÈÜÒº»ñÅúÉÏÊÐ

½ñÈÕ£¬ÉϺ£º£ºÍÒ©ÎïÑо¿¿ª·¢¹É·ÝÓÐÏÞ¹«Ë¾£¨ÒÔϼò³Æ“º£ºÍÒ©Î©ºÍº«¹ú´ó»¯ÖÆÒ©¹«Ë¾£¨ÒÔϼò³Æ“´ó»¯ÖÆÒ©”£©¹²Í¬Ðû²¼£ºË«·½ºÏ×÷¿ª·¢µÄ×Ïɼ´¼¿Ú·þÈÜÒº(Ñз¢´úºÅ£ºRMX3001)»ñµÃ¹ú¼ÒÒ©Æ·¼à¶½¹ÜÀí¾Ö£¨NMPA£©Åú×¼ÔÚÖйú´ó½ÉÏÊУ»ÓÃÓÚÒ»Ïߺ¬·úÄòà×à¤Àà·½°¸ÖÎÁÆÆÚ¼ä»òÖÎÁƺó³öÏÖ¼²²¡½øÕ¹µÄÍíÆÚθ°©»¼ÕßµÄÖÎÁÆ¡£

 

RMX3001×÷ΪȫÇòµÚÒ»¿îÑз¢³É¹¦µÄ¿Ú·þ¼ÁÐÍ×Ïɼ´¼Ò©ÎÆäÁÆЧÒѾ­ÔÚº«¹úIIIÆÚÁÙ´²Ñо¿DREAMÑо¿Öеõ½¿Ï¶¨£¬²¢ÔÚº«¹ú»ñÅúÓÃÓÚθ°©¶þÏßÖÎÁÆ¡£ÔÚÖйúÒÔÈ«¹úLeading PIÀî½ø½ÌÊÚÍŶӺÍÇØÊååÓ½ÌÊÚÍŶÓÁìÏεÄÒ»Ï·Å¡¢Ëæ»ú¶ÔÕÕ¡¢¶àÖÐÐĵÄIIIÆÚÑо¿£¨CTR20190050£©ÖУ¬ÔÙ´Î֤ʵ×Ïɼ´¼¿Ú·þÈÜÒº¶Ô¾­Ò»ÏßÖÎÁƺóµÄ²»¿ÉÊÖÊõÇгý¡¢¸´·¢»òתÒÆÐÔÍíÆÚθ°©ÁÆЧÃ÷È·¡¢°²È«¿É¿Ø¡£

 

´Ó2019Äê4ÔÂ22ÈÕÖÁ2022Äê1ÔÂ31ÈÕ£¨Êý¾Ý½ØÖ¹ÈÕÆÚ£©£¬¸ÃÑо¿ÓÉ53¼ÒÖÐÐĹ²Èë×é536Àý»¼Õߣ¬×Ïɼ´¼¿Ú·þÈÜÒºÊÔÑé×éºÍ×Ïɼ´¼×¢ÉäÒº¶ÔÕÕ×é·Ö±ð268Àý»¼Õߣ¬ÖÐλËæ·Ãʱ¼ä·Ö±ðΪ13.4¸öÔ ºÍ 12.6¸öÔ¡£ÓÉä̬¶ÀÁ¢Ó°ÏñÆÀ¹ÀίԱ»á£¨BIRC£©ÆÀ¹ÀµÄÖÐλÎÞ½øÕ¹Éú´æÆÚ£¨mPFS£©ÊÔÑé×éΪ3.02¸öÔ¶ԱȶÔÕÕ×é2.89¸öÔ£¬×Ïɼ´¼¿Ú·þÈÜÒº²»ÁÓÓÚ×Ïɼ´¼×¢ÉäÒº£¨HR 0.894£¬95% CI£º0.719, 1.112£¬p=0.311£©¡£½ØÖ¹2023Äê2ÔÂ15ÈÕ£¬ÖÐλ×ÜÉú´æʱ¼ä£¨mOS£©ÊÔÑé×éΪ9.13¸öÔ¶ԱȶÔÕÕ×é6.54¸öÔ£¬×Ïɼ´¼¿Ú·þÈÜÒºÓÅÓÚ×Ïɼ´¼×¢ÉäÒº£¬ÖÐλOSÑÓ³¤ÁË2.59¸öÔ£¨HR 0.770, 95.5% CI: 0.635, 0.934, p=0.006£©¡£°²È«ÐÔ·½Ã棬ÕûÌ尲ȫÄÍÊÜ£¬³£¼û≥3¼¶²»Á¼Ê¼þΪÖÐÐÔÁ£Ï¸°û¼ÆÊý¼õµÍ£¬°×ϸ°û¼ÆÊý¼õµÍµÈѪҺ¶¾ÐÔ¡£ÔÚÍÑ·¢¡¢ÍâÖÜÉñ¾­²¡±ä¡¢·¦Á¦¡¢¸÷ÖÖ¼¡Èâ¹Ç÷À¼°½áµÞ×éÖ¯¼²²¡¡¢¹ýÃô·´Ó¦µÈ¸±·´Ó¦·½Ãæ×Ïɼ´¼¿Ú·þÈÜÒº±íÏÖ³ö·¢ÉúÂʼõµÍÓÅÊÆ¡£

 
º£ºÍÒ©ÎïÊ×ϯִÐйٶ­Èðƽ²©Ê¿±íʾ£º
“RMX3001ÊǹúÄÚÊ׿î»ñÅúµÄ×Ïɼ´¼¿Ú·þÈÜÒº£¬ÎÒÃǺܸßÐË¿´µ½ÆäÔÚÁÙ´²Ñо¿ÖÐÕ¹ÏÖ³öµÄÏÔÖøÁÆЧ²¢¼æ¾ßºÜºÃµÄÄÍÊÜÐÔ£»¸ø»¼Õß´øÀ´³ÖÐøÁÆЧ»ñÒæµÄͬʱ£¬Ìá¸ß»¼ÕßµÄÉú»îÖÊÁ¿¡£ÎÒÃÇÖÔÐĸÐл²ÎÓëÑо¿µÄ»¼Õß¼°Æä¼ÒÊô£¬ËùÓÐÑо¿ÕßÃÇ£¬Ò²·Ç³£¸Ðл´ó»¯ÖÆÒ©µÄÖ§³Ö¡¢ºÏ×÷»ï°éÃdz¤¾ÃÒÔÀ´¶ÔÎÒÃǵÄÖ§³Ö¼°²»Ð¸µÄŬÁ¦¡£º£ºÍÖÂÁ¦ÓÚΪÖ×Áö»¼ÕßÌṩ¸üºÃµÄÒ©Îï¡£Ò²ÆÚ´ýÕâ¿î×Ïɼ´¼¿Ú·þÒ©ÎïÄܹ»»ñÅúÓÃÓÚ¶à¸öÖ×ÁöÀàÐÍ£¬Ô츣¸ü¶àµÄ»¼Õߣ¡”
 
×¢²áÑо¿µÄÈ«¹úCo-PIs£¬ÖйúÒ©¿Æ´óѧ¸½ÊôÄϾ©ÌìӡɽҽԺÇØÊååÓ½ÌÊÚÐÀϲµØ±íʾ£º
“ÈÈÁÒ×£ºØ×Ïɼ´¼¿Ú·þÈÜÒº¾­¹ýÑϸñ¹æ·¶µÄÁÙ´²ÊÔÑ飬»ñµÃÁËNMPAÅú×¼ÉÏÊУ¬ÓÃÓÚÖÎÁÆÍíÆÚθ°©£¡×÷ΪÖйúµÚÒ»¿î»ñÅúÉÏÊеĿڷþ¼ÁÐÍ×Ïɼ´¼£¬Ìî²¹ÁËÓйØÁìÓòµÄ¿Õ°×¡£¸ÃÒ©È·ÇÐÓÐЧ£¬°²È«ÐԺã¬ÇÒʹÓ÷½±ã£¬¼«´óµØÌá¸ßÁË»¼ÕßµÄÄÍÊÜÐÔºÍÒÀ´ÓÐÔ£¬ÏàÐÅ¿ÉÒԺܺõؽâ¾öÆÈÇеÄÁÙ´²ÐèÇó£¬Ô츣¹ã´óÖ×Áö»¼Õߣ¬ÖµµÃ»ý¼«ÍƹãÓ¦Óᣔ
 
ÖйúÒ©¿Æ´óѧ¸½ÊôÉϺ£¸ß²©Ö×ÁöÒ½ÔºÀî½ø½ÌÊÚ±íʾ£º
“·Ç³£¸ßÐË¿´µ½¿Ú·þ¼ÁÐ͵Ä×Ïɼ´¼Ò©Îï»ñµÃNMPAÅú×¼£¬ÕâÊÇ0µ½1µÄÍ»ÆÆ¡£¸ø»¼Õß´øÀ´¿Ú·þ±ã½ÝµÄͬʱ£¬Ò²´ó´óÌá¸ßÁËÁÙ´²ÁÆЧ£¬½µµÍ²»Á¼·´Ó¦µÄ·¢ÉúÂÊ£¬Ìá¸ß»¼ÕßµÄÉú»îÖÊÁ¿£¡”
 
¹ØÓÚ×Ïɼ´¼¿Ú·þÈÜÒº£¨Ñз¢´úºÅ£ºRMX3001/DHP107£©

×Ïɼ´¼ÊÇÓ¦ÓÃ×îΪ¹ã·ºµÄ»¯ÁÆÒ©ÎïÖ®Ò»£¬Êг¡ÐèÇó¾Þ´ó¡£Ä¿Ç°¹úÄÚ¸ÃÒ©ÎïµÄÉÏÊмÁÐ;ùΪעÉä¼Á £¬Ðè¾­ÅäÖƺóÔÚÒ½Ôº¾­¾²ÂöµÎ×¢¸øÒ©£¬»¼ÕßÐèƵ·±·µÔº£¬ÇÒ»áÓÐ×¢É䲿λ²»Á¼·´Ó¦£¬Òò´Ë¿Ú·þ×Ïɼ´¼ÖƼÁµÄ¿ª·¢Ò»Ö±ÊÇÐÐÒµÑо¿µÄÈȵã¡£¸Ã²úÆ·ÊÇÓÉ´ó»¯ÖÆÒ©»ùÓÚÆ䴴еÄÖ¬ÖÊ×ÔÈ黯ҩÎïµÝËͼ¼Êõ¿ª·¢¶ø³ÉµÄ×Ïɼ´¼¿Ú·þÖƼÁ£¬ÓÚ2016Äê9ÔÂ9Èճɹ¦»ñµÃº«¹úÒ©¼à»ú¹¹£¨MFDS£©µÄÉÏÊÐÅú×¼£¬ÊÊӦ֢ΪÍíÆÚ»òתÒÆÐÔθ°©»ò¾Ö²¿¸´·¢ÐÔθ°©¶þÏßÖÎÁÆ¡£½ØֹĿǰ£¬RMX3001ÊÇÈ«ÇòµÚÒ»¸ö¿ª·¢³É¹¦²¢»ñÅúÉÏÊеĿڷþ×Ïɼ´¼²úÆ·¡£º£ºÍÒ©ÎïÓÚ2017Äê9Ô´Ӵó»¯ÖÆÒ©»ñµÃ¸Ã²úÆ·µÄÖйú´ó½¡¢Ì¨Íå¡¢Ïã¸Û¼°Ì©¹úÑз¢¡¢Éú²ú¼°ÏúÊÛȨÒæ¡£

¹ØÓÚθ°©

θ°©ÊÇÈ«ÇòµÚÎå´ó×î³£¼ûµÄ¶ñÐÔÖ×Áö£¬·¢²¡Âʸߣ¬Ô¤ºó²î£¬ÑÏÖØÍþвÈËÀཡ¿µ¡£2022ÄêÈ«ÇòÔ¼97Íòθ°©Ð·¢²¡Àý£¬ËÀÍö²¡ÀýÔ¼66Íò¡£ÔÚÖйúθ°©Ð·¢²¡Ô¼36Íò£¬¾ÓµÚÎå룬ËÀÍö²¡ÀýÔ¼26Íò£¬¾ÓµÚÈýλ£¬È«Çò½«½ü40%µÄθ°©ÔÚÖйú1-3¡£ÍíÆÚθ°©¼«Ò×·¢ÉúתÒÆ£¬»òÔì³É¸¹Ë®¡¢ÑÏÖØÏûÊÝ¡¢Å»ÑªµÈÖ¢×´±íÏÖ£¬»¼ÕßÉú»îÖÊÁ¿ºÜ²î£¬¾­ÀúÑÏÖØÍ´¿à4¡£Ä¿Ç°¹ØÓÚÍíÆÚθ°©µÄ¶þÏßÖÎÁÆ£¬µ¥Ò©×Ïɼ´¼ÊÇÃÀ¹ú¹ú¼Ò×ۺϰ©Ö¢ÍøÂ磨NCCN£©Î¸°©Ö¸ÄϺÍÖйúÁÙ´²Ö×Áöѧ»á£¨CSCO£©Î¸°©Ö¸ÄÏI¼¶ÍƼö4, 5¡£

¹ØÓÚAG¡¤×ðÁú¿­Ê± - ÈËÉú¾ÍÊDz«!

º£ºÍÒ©ÎïÊÇÖйúÁìÏȵÄ×ÔÖ÷´´ÐÂÉúÎï¼¼Êõ¹«Ë¾£¬×¨×¢ÓÚ¿¹Ö×Áö´´ÐÂÒ©ÎïµÄ·¢ÏÖ¡¢¿ª·¢¡¢Éú²ú¼°ÉÌÒµ»¯£¬Ï£ÍûΪȫÇò°©Ö¢»¼Õß´øÀ´¸ü°²È«¡¢¸üÓÐЧµÄÖÎÁÆ·½·¨¡£AG¡¤×ðÁú¿­Ê± - ÈËÉú¾ÍÊDz«!¼á³Ö×ß×ÔÖ÷´´ÐµĵÀ·£¬Í¬Ê±ÓµÓÐÒ»Ö§¾ßÓÐÈ«Çò»¯ÊÓÒ°µÄ¿ÆÑк͹ÜÀíÍŶӣ¬»ý¼«²¼¾Ö´´ÐÂÒ©ÎïµÄ¹ú¼Ê¿ª·¢Ö®Â·¡£Ä¿Ç°º£ºÍÒ©ÎïÒÑÓÐ2¿î²úÆ·»ñ×¼ÉÏÊУº1.¹ÈÃÀÌæÄáƬ£¬ÖÐÎÄÉÌÆ·Ãû£ºº£Òæ̹®£¬ÈÕ±¾ÉÌÆ·Ãû£º¥Ï¥¤¥¤©`¥¿¥ó®åV50©J£¬ÒÑÕýʽÔÚÖйúºÍÈÕ±¾¾ù»ñÅúÉÏÊУ»2.×Ïɼ´¼¿Ú·þÈÜÒºÒÑÕýʽÔÚÖйú»ñÅúÉÏÊС£Áí£¬º£ºÍÒ©ÎïͬʱÓжà¸öÔÚÑÐÖصã¹ÜÏߵĺòÑ¡Ò©Îï¡£

¹ØÓÚ´ó»¯ÖÆÒ©

´ó»¯ÖÆÒ©µÄ´´Á¢Ö¼ÔړΪÉç»áÌṩ¸ü¼ÓÒÔÈËΪ±¾µÄÖÆÒ©ÆóÒµ”£¬ÆäÖ÷ҪĿ±êÊǸÄÉƹúÃñ½¡¿µºÍÈËÃñÉú»î¡£×Ô1984Äê³ÉÁ¢ÒÔÀ´£¬¹«Ë¾²»¶ÏÑ°ÇóеÄÒµÎñ·¢Õ¹Í¾¾¶£¬²¢¼á³ÖÒÔ³ÖÐøµÄ·¢Õ¹Îªµ¼ÏòÕâÒ»ºËÐÄÄ¿±ê¡£ ƾ½è×Ô¼ºµÄƽ̨£¨DHLASED£©¼¼Êõ£¬´ó»¯ÖÆÒ©Éú²úÖÚ¶àµÄÖƼÁ³ÉÆ·¡£×Ïɼ´¼¿Ú·þÈÜÒº£¨Liporaxel®£©ÊÇ´ó»¯ÖÆÒ©Ê®ÆßÄêÑо¿µÄ³É¹û£¬ÒÑÍê³ÉµÄÁÙ´²ÊÔÑé³ä·ÖÖ¤Ã÷ÁËËüµÄÁÆЧ¡¢°²È«ÐԺͱãÀûÐÔ¡£´ó»¯ÖÆÒ©½«Æ䳬¹ý10£¥µÄÏúÊÛ¶îͶÈëÑз¢£¬ÊÇÒ»¼Ò¼¯Ò½Ò©²úÆ·Ñо¿¡¢Éú²ú¡¢ÏúÊÛÓÚÒ»ÉíµÄÒ½Ò©²úÆ·µÄÈ«ÇòÐÔ¹«Ë¾¡£

¸ü¶àÐÅÏ¢£¬Çë·ÃÎÊ´ó»¯ÖÆÒ©¹«Ë¾ÍøÕ¾£º

http://www.dhpharm.co.kr

²Î¿¼ÎÄÏ×£º

  1. Globocan 2022: Absolute numbers, Incidence/Mortality, Both sexes, in 2022. https://gco.iarc.fr/today/en/dataviz/pie?mode=cancer&group_populations=1.
  2. Bray F, Laversanne M, Sung H, et al: Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229-263, 2024
  3. National Cancer Institute. Surveillance, Epidemiology, and End Results Program Cancer Stat Facts: Stomach Cancer. SEER 2014–2020. https://seer.cancer.gov/statfacts/html/stomach.html.
  4. Wang FH, Zhang XT, Tang L, et al: The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer Commun (Lond) 44:127-172, 2024
  5. NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer, Version 3.2023-January 26,2024. https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf.
| ·¨ÂÉÉùÃ÷ | ÃâÔðÉùÃ÷ | ÁªÏµÎÒÃÇ | Ò½Ò©´ú±í±¸°¸¹«Ê¾ |
¹Ø×¢ÎÒÃÇ
?2020 ÉϺ£º£ºÍÒ©ÎïÑо¿¿ª·¢¹É·ÝÓÐÏÞ¹«Ë¾
°æȨËùÓÐ »¦ICP±¸12016151ºÅ-1
¡¾ÍøÕ¾µØͼ¡¿¡¾sitemap¡¿
ÓÑÇéÁ´½Ó£º×ðÁú¿­Ê±ÈËÉú¾ÍÊDz©z6com¡¤(ÖйúÇø)¹Ù·½ÍøÕ¾  Z6¡¤×ðÁú¿­Ê±¡¸Öйú¡¹¹Ù·½Íø  ÈËÉú¾ÍÊDz©-×ðÁú¿­Ê±Öйú¹ÙÍø  ×ðÁú¿­Ê± - ¹ÙÍøÊ×Ò³ --?ÈËÉú¾ÍÊDz©!  ×ðÁú¿­Ê±ÈËÉú¾ÍÊDz«¡¤¡¸ÖйúÇø¡¹°Ù¶È°Ù¿Æ  ×ðÁú¿­Ê±ÈËÉú¾ÍÊDz©¡¤Öйú-(Öйú)°Ù¶È°Ù¿Æ  Z6¡¤×ðÁú¿­Ê±¡¸Öйú¡¹¹Ù·½ÍøÕ¾  ×ðÁú¿­Ê± - ÈËÉú¾ÍÊDz«!